RAD140
Synonym:RAD140; 2-chloro-4-[[(1r,2s)-1-[5-(4-cyanophenyl)-1,3,4-oxadiazol-2-yl]-2-hydroxypropyl]amino]-3-methylbenzoni
CAS:1182367-47-0
MW:393.826
MF:C20H16ClN5O2
Purity:99.5%(HPLC)
Product Categories:SARMs(Selective androgen receptor modulator)
Apprarance:White crystalline powder.
Application:
RAD140 is a highly effective, oral SARM (Selective Androgen Receptor Modulator) currently being studied for both anabolic and neuroprotective effects. It is in a class of androgen receptor (AR) ligands that are tissue selective, developed to treat muscle wasting associated with cancer, acute and chronic illness and age-related muscle loss. Recent research of RAD140 shows superior lean tissue selectivity, and reduced androgenic side effects when compared to competing SARM compounds. This compound provides is being studied for neuroprotection as well; an important neural action of endogenous androgens that is relevant to neural health and resilience to neurodegenerative diseases, and to be as effective as testosterone in reducing cell death induced by apoptotic insults.
Easy to dose oral SARM that increases lean mass while remaining tissue selective in current research
Added value for research with pronounced neuroprotective properties
Myotrophic and neuroregeneration research compound
SARM RAD140 the most anabolic selective androgen receptor modulator available.
RAD 140 is a SARM that is designed to act as if the tissues of the body are getting a good dose of testosterone without the unwanted side effects of anabolic steroids. It has been shown to enhance speed, stamina and endurance during workouts as well as increase muscular gains within shorter periods of time.
Name CAS NO. Usage
AICAR 2627-69-2 acts by entering nucleoside pools, significantly increasing levels of adenosine during periods of ATP breakdown
MK2866 841205-47-8 medical prescription for prevention of cachexia, atrophy, and sarcopenia and for Hormone or Testoserone Replacement Therapy.
MK-677 15972-10-0 A growth hormone secretagogue, treatment of obesity, a promising therapy for the treatment of frailty in the elderly
LGD-4033 1165910-22-4 pharmacological profile similar to that of enobosarm, Ostarine,MK-2866
GW1516 317318-70-0 For obesity, diabetes, dyslipidemia and cardiovascular disease
Andarine(S4) 401900-40-0 partial agonist, intended mainly for treatment of benign prostatic hypertrophy
SR9009 1379686-30-2 under development at The Scripps Research Institute (TSRI), increases the level of metabolic activity in skeletal muscles of mice
SR9011 1379686-30-2 For obesity, diabetes, dyslipidemia and cardiovascular disease
RAD140 1182367-47-0 New generation for gaining mass and cutting edges
YK11 366508-78-3 YK11: a SARM and myostatin inhibitor in one
431579-34-9
Permanent link: http://www.vvchem.com/sell/cas:1182367-47-0,3320663.html
China
